Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 4/2016

Open Access 01-12-2016 | special report

Soft tissue sarcomas & GIST

Highlights from ASCO meeting 2016

Authors: Sophie Roider-Schur, Rainer Hamacher, Thomas Brodowicz

Published in: memo - Magazine of European Medical Oncology | Issue 4/2016

Login to get access

Summary

Soft tissue sarcomas (STS) are a rare and heterogeneous disease sharing mesenchymal origin. While classification of different STS subtypes has generated insight into their molecular pathogenesis, treatment response, and prognosis, oncological management still poses major clinical challenges. Despite considerable evolution in definition of optimal treatment strategies over the past decade there is a critical need of new and less toxic therapeutic approaches for the treatment of metastatic sarcoma. This review covers the latest clinical study highlights for soft tissue sarcomas and gastroinestinal stromal tumours (GIST) presented at ASCO 2016, demonstrating a constant progress from conventional chemotherapy to histology-tailored therapy as well as immunotherapy approaches.
Literature
1.
Group, E.S.E.S.N.W. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii102–iii112.CrossRef
2.
Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol. 2010;21(Suppl 7):vii270–vii276.PubMed
3.
Reichardt P. Soft tissue sarcomas, a look into the future: different treatments for different subtypes. Future Oncol. 2014;10(8 Suppl):s19–s27.CrossRef
4.
Group, E.S.E.S.N.W.. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii21–iii26.CrossRef
5.
van der Graaf WT, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.CrossRef
6.
Weber JS, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.CrossRef
7.
D’Angelo SP. Manipulating the immune system with checkpoint inhibitors for patients with metastatic sarcoma. Am Soc Clin Oncol Educ Book. 2016;35:e558–e564.CrossRef
8.
Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–7.CrossRef
9.
Penel N. Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial. J Clin Oncol. 2016;34:(suppl; abstract 11003).CrossRef
10.
Schmoll HJ. Pazopanib vs pazopanib + gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO. J Clin Oncol. 2016;34:(suppl; abstr 11003).CrossRef
11.
Tawbi HA-H. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028– A multicenter phase II study. J Clin Oncol. 2016;34:(suppl; abstr 1106).CrossRef
12.
Lin Z, et al. PD-1 antibody monotherapy for malignant melanoma: A systematic review and meta-analysis. PLOS ONE. 2016;11(8):e0160485.CrossRef
13.
George S. Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus. J Clin Oncol. 2016;34:(suppl; abstr 11007).CrossRef
14.
Von Mehren M. Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations. J Clin Oncol. 2016;34:(suppl; abstr 11007).CrossRef
15.
DeMatteo RP, Targeting IDO. A novel immune checkpoint in GIST. oral presentation. 2016.
16.
Balachandran VP, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17(9):1094–100.CrossRef
17.
Blay J‑Y. Improved sarcoma management in a national network of reference centers: Analysis of the NetSarc network on 13,454 patients treated between 2010 and 2014. J Clin Oncol. 2016;34:(suppl; abstr 11013).CrossRef
Metadata
Title
Soft tissue sarcomas & GIST
Highlights from ASCO meeting 2016
Authors
Sophie Roider-Schur
Rainer Hamacher
Thomas Brodowicz
Publication date
01-12-2016
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 4/2016
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0287-z

Other articles of this Issue 4/2016

memo - Magazine of European Medical Oncology 4/2016 Go to the issue

short review

PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view

short review

Short overview on the current treatment of chronic myeloid leukemia in chronic phase

short review

Therapy for EGFR tyrosine kinase inhibitor-resistant NSCLC with a focus on the T790M-resistant mutation

short review

ASCO update: gastric cancer

special report

Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer

short review

Extravasation emergencies: state-of-the-art management and progress in clinical research
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits